Oncotarget

A discussion of how aramchol, regorafenib, and metformin work together to kill uveal melanoma and cholangiocarcinoma cells. They highlight a triple-drug boost in autophagosome formation and autophagic flux. The conversation touches on molecular contributors like BID and autophagy genes. They also consider aramchol actions beyond SCD1 and potential for treating liver metastases.

A deep dive into using machine learning to predict colorectal cancer survival by merging clinical records with molecular markers. They cover which data sources and preprocessing steps matter and how features like genes and non-coding RNAs are identified. The conversation reviews model choices, accuracy results, and the challenges of validation and population bias.

Researchers discuss how CREB5 ties to basal-like and stem cell-like transcriptional programs in prostate cancer. They explore CREB5's interaction with AP-1 factors and binding to regulatory elements. The conversation covers how CREB5 overexpression boosts colony formation and tumor growth. They consider CREB5's early presence in tumors and implications for therapy resistance and future targeting strategies.

BUFFALO, NY – March 16, 2025 – Impact Journals (publisher of Aging-US, Oncotarget, Oncoscience, and Genes & Cancer), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2026. The meeting will take place April 17–22, 2026, at the San Diego Convention Center in San Diego, CA. Conference attendees are warmly invited to visit Booth 3641 to meet members of the Impact Journals team, discover notable recent publications, and discuss opportunities for collaboration. The mission of Impact Journals is to maximize research impact through insightful peer review, eliminate borders between specialties by linking different fields of oncology and biomedical science, and foster the application of both basic and clinical science. This mission is grounded in a strong commitment to ethical standards and scientific integrity. At Impact Journals, evolving digital technologies, tools, and ideas are continually integrated into a robust scientific integrity process. The AACR Annual Meeting serves as a focal point for the global cancer research community, bringing together scientists, clinicians, healthcare professionals, survivors, patients, and advocates to share the latest advances in cancer science and medicine. From population science and prevention to cancer biology, translational and clinical studies, survivorship, and advocacy, the AACR Annual Meeting highlights the work of leading researchers from institutions around the world. To learn more about Impact Journals, please visit impactjournals.com. For media inquiries, email media@impactjournals.com.

Engineered T cells are framed as precision soldiers attacking cancer with detailed clinical workflow steps. The show highlights striking successes in blood cancers and early efforts against solid tumors. Serious toxicities, therapy resistance, and access inequalities are discussed. Future developments include safety switches, donor-derived products, and platform improvements.

A detailed case study and literature review exploring reports of blood cancers after mRNA COVID-19 vaccination. Covers patient timelines, diagnostic imaging, treatment and relapse. Surveys patterns of post‑vaccination malignancies and timing. Discusses proposed biological mechanisms like immune checkpoint changes, spike protein interactions with tumor suppressors, and interferon signaling alterations.

Cutting-edge CAR-T designs and how they could reshape cancer care are explored. The workflow from cell collection to genetic reprogramming and infusion is outlined. Obstacles in solid tumors like antigen choice and the tumor microenvironment are highlighted. Innovative strategies such as dual-targeting constructs, switchable systems, and ways to reduce toxicities and improve access are discussed.

A commentary chronicles a two-year struggle to publish a case report linking an mRNA COVID-19 vaccine to a rare blood cancer. It details repeated rejections, alleged withdrawals after positive review, and examples of reviewer comments that the authors say misrepresented their work. The piece questions whether editorial choices shaped the perceived scientific consensus and calls for more transparent publishing practices.

A detailed case recounts rapid onset of aggressive blood cancer in a healthy woman soon after a second mRNA COVID-19 vaccine dose. The discussion highlights similar rare reports of leukemias and lymphomas appearing after vaccination. Possible immune-related mechanisms and concerns about lipid nanoparticle distribution are explored. The need for further long-term safety research is emphasized.

A deep dive into how p53, the cell’s cancer gatekeeper, can be targeted by viral proteins. Discussion of HPV E6’s p53 degradation alongside possible effects of SARS-CoV-2 spike on p53 activity. Lab observations, a clinical anecdote, and implications for HPV-positive patients are explored. Research gaps and experiments needed to test the proposed cooperative suppression are outlined.